Teleflex Incorporated (NYSE: TFX) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -22.80 | Insider Own | 0.89% | Shs Outstand | 44.27M | Perf Week | 4.41% |
| Market Cap | 6.20B | Forward P/E | 13.24 | EPS next Y | 10.58 | Insider Trans | 0.00% | Shs Float | 43.91M | Perf Month | 4.32% |
| Enterprise Value | 8.58B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 6.34% | Perf Quarter | 16.87% |
| Income | -1.01B | P/S | 2.21 | EPS this Y | 129.25% | Inst Trans | - | Short Ratio | 3.92 | Perf Half Y | 35.57% |
| Sales | 2.81B | P/B | 2.01 | EPS next Y | 58.69% | ROA | -14.87% | Short Interest | 2.78M | Perf YTD | 14.81% |
| Book/sh | 69.66 | P/C | 20.07 | EPS next 5Y | 19.70% | ROE | -28.27% | 52W High | 144.19 -2.82% | Perf Year | 20.91% |
| Cash/sh | 6.98 | P/FCF | 24.30 | EPS past 3/5Y | - | ROIC | 2.73% | 52W Low | 100.18 39.87% | Perf 3Y | -44.47% |
| Dividend Est. | 1.36 (0.97%) | EV/EBITDA | - | Sales past 3/5Y | -10.62% -4.71% | Gross Margin | 53.27% | Volatility | 3.51% 3.07% | Perf 5Y | -65.17% |
| Dividend TTM | 1.36 (0.97%) | EV/Sales | 3.05 | EPS Y/Y TTM | -1640.54% | Oper. Margin | 6.48% | ATR (14) | 4.42 | Perf 10Y | -20.45% |
| Dividend Ex-Date | May 22, 2026 | Quick Ratio | 2.03 | Sales Y/Y TTM | -7.75% | Profit Margin | -35.89% | RSI (14) | 62.23 | Recom | 2.48 |
| Dividend Gr. 3/5Y | 0.00% 0.00% | Current Ratio | 2.55 | EPS Q/Q | -52.23% | SMA20 | 4.41% | Beta | 0.79 | Target Price | 152.57 |
| Payout | -5.96% | Debt/Eq | 0.87 | Sales Q/Q | -21.83% | SMA50 | 6.71% | Rel Volume | 1.06 | Prev Close | 139.70 |
| Employees | 15,500 | LT Debt/Eq | 0.84 | Earnings | Aug 06 | SMA200 | 15.50% | Avg Volume | 570.34K | Price | 140.12 |
| IPO Date | Mar 17, 1980 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 14.53% 2.12% | Net Debt/EBITDA | -26.86 | Volume | 604,857 | Change | 0.30% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-31-26 | Reiterated | Needham | Buy | $147 → $159 |
| Jul-28-26 | Initiated | UBS | Neutral | $145 |
| Jul-08-26 | Initiated | BMO Capital | Outperform | $159 |
| Jun-08-26 | Upgrade | Piper Sandler | Neutral → Overweight | $245 → $160 |
| May-08-26 | Reiterated | Raymond James | Outperform | $128 → $150 |
| May-08-26 | Reiterated | Mizuho Securities | Neutral | $135 → $140 |
| May-08-26 | Upgrade | RBC Capital | Sector Perform → Outperform | $135 → $155 |
| Mar-27-26 | Upgrade | Raymond James | Market Perform → Outperform | $355 → $128 |
| Feb-26-26 | Reiterated | Needham | Buy | $138 → $147 |
| Jan-29-26 | Reiterated | Wells Fargo | Equal Weight | $139 → $116 |
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,811 | 1,993 | 3,047 | 2,974 | 2,791 | 2,810 | 2,537 | 2,595 | 2,448 | |
| Cost of Goods Sold Incl. D&A | 1,314 | 872 | 1,345 | 1,328 | 1,260 | 1,260 | 1,212 | 1,186 | 1,064 | |
| Gross Profit | 1,497 | 1,121 | 1,703 | 1,647 | 1,531 | 1,550 | 1,325 | 1,409 | 1,384 | |
| Selling, General and Administrative Excl. Other | 945 | 720 | 995 | 930 | 864 | 860 | 744 | 852 | 879 | |
| Research and Development | 189 | 145 | 162 | 154 | 154 | 131 | 120 | 114 | 106 | |
| Other Operating Expense | 181 | 0 | 395 | 57 | 13 | -69 | 38 | 16 | 0 | |
| Operating Income | 181 | 256 | 151 | 506 | 500 | 628 | 423 | 427 | 322 | |
| Interest Expense | 114 | 100 | 84 | 85 | 54 | 57 | 66 | 80 | 103 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -388 | -131 | 8 | 13 | 0 | -12 | 1 | -7 | 1 | |
| Net Income Before Taxes | -320 | 25 | 75 | 434 | 446 | 559 | 358 | 340 | 220 | |
| Income Taxes | -25 | -34 | 5 | 76 | 83 | 74 | 22 | -122 | 23 | |
| Consolidated Net Income | -1,008 | -906 | 70 | 356 | 363 | 485 | 335 | 461 | 201 | |
| Net Income From Continuing Operations | -295 | 59 | 70 | 358 | 363 | 485 | 336 | 462 | 196 | |
| Net Income | -1,008 | -906 | 70 | 356 | 363 | 485 | 335 | 461 | 201 | |
| EPS (Recurring) | -22.80 | -20.30 | 1.49 | 7.58 | 7.74 | 10.38 | 7.21 | 9.99 | 4.39 | |
| EPS (Basic, Before Extraordinaries) | -22.80 | -20.30 | 1.49 | 7.58 | 7.74 | 10.38 | 7.21 | 9.99 | 4.39 | |
| EPS (Diluted) | -22.80 | -20.25 | 1.48 | 7.53 | 7.68 | 10.23 | 7.09 | 9.80 | 4.29 | |
| EBITDA | -88 | 303 | 434 | 761 | 731 | 854 | 651 | 634 | 533 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 120.26 | 33.11 | 32.50 | 32.11 | 58.05 | 38.41 | 60.25 | |
| Price To Sales Ratio | 2.19 | 2.76 | 2.75 | 3.94 | 4.20 | 5.49 | 7.46 | 6.67 | 4.86 | |
| Gross Margin | 53.26 | 56.25 | 55.89 | 55.38 | 54.85 | 55.16 | 52.23 | 54.30 | 56.54 | |
| Operating Margin | 6.44 | 12.84 | 4.96 | 17.01 | 17.91 | 22.35 | 16.67 | 16.45 | 13.15 | |
| Net Margin | -35.86 | -45.46 | 2.30 | 11.97 | 13.01 | 17.26 | 13.20 | 17.76 | 8.21 | |
| Shares Outstanding | 44 | 45 | 47 | 47 | 47 | 47 | 46 | 46 | 46 | |
| Market Capitalization | 6,165 | 5,492 | 8,365 | 11,719 | 11,733 | 15,439 | 18,932 | 17,316 | 11,890 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| HAGGERTY GRETCHEN R | Director | Aug 06 '25 | Buy | 114.75 | 500 | 57,375 | 6,305 | Aug 07 |
| Ryu Jaewon | Director | Aug 05 '25 | Buy | 115.00 | 1,500 | 172,500 | 3,727 | Aug 07 |
| Krakauer Andrew A | Director | Aug 05 '25 | Buy | 115.25 | 1,000 | 115,250 | 7,192 | Aug 07 |
| Kelly Liam | Chairman, President & CEO | Aug 05 '25 | Buy | 115.07 | 1,500 | 172,605 | 45,267 | Aug 07 |
| RANDLE STUART A | Director | Aug 05 '25 | Buy | 115.86 | 1,000 | 115,860 | 7,547 | Aug 07 |
| Duncan Candace H | Director | May 05 '25 | Option Exercise | 123.04 | 4,833 | 594,652 | 9,561 | May 07 |
| Logue Daniel V. | CVP, General Counsel & Secty | Feb 20 '25 | Option Exercise | 121.00 | 1,620 | 196,020 | 14,328 | Feb 21 |
| Klasko Stephen K. M.D. | Director | Feb 20 '25 | Option Exercise | 121.00 | 2,674 | 323,554 | 9,827 | Feb 21 |
| Kelly Liam | Chairman, President & CEO | Feb 19 '25 | Option Exercise | 121.41 | 36,464 | 4,427,199 | 63,556 | Feb 21 |
| RANDLE STUART A | Director | Aug 16 '24 | Option Exercise | 121.00 | 2,674 | 323,554 | 8,170 | Aug 16 |
| RANDLE STUART A | Director | Aug 16 '24 | Sale | 238.93 | 2,674 | 638,899 | 5,496 | Aug 16 |
| Hicks Cameron P | Corp. VP & Chief HR Officer | Mar 05 '24 | Option Exercise | 135.14 | 7,401 | 1,000,197 | 17,451 | Mar 05 |
| Hicks Cameron P | Corp. VP & Chief HR Officer | Mar 05 '24 | Sale | 225.00 | 7,401 | 1,665,225 | 10,050 | Mar 05 |
| Logue Daniel V. | CVP, General Counsel & Secty | Feb 26 '24 | Option Exercise | 101.12 | 1,525 | 154,208 | 12,278 | Feb 28 |
| Kelly Liam | Chairman, President & CEO | Dec 27 '23 | Option Exercise | 101.87 | 26,256 | 2,674,571 | 44,726 | Dec 29 |